Catalyst Pharmaceuticals Valuation
| CPRX Stock | USD 21.15 0.24 1.12% |
At this time, the firm appears to be fairly valued. Catalyst Pharmaceuticals shows a prevailing Real Value of $21.4 per share. The current price of the firm is $21.15. Our model approximates the value of Catalyst Pharmaceuticals from analyzing the firm fundamentals such as Current Valuation of 2.08 B, return on equity of 0.28, and Profit Margin of 0.31 % as well as examining its technical indicators and probability of bankruptcy.
Fairly Valued
Today
Please note that Catalyst Pharmaceuticals' price fluctuation is very steady at this time. Calculation of the real value of Catalyst Pharmaceuticals is based on 3 months time horizon. Increasing Catalyst Pharmaceuticals' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Catalyst Pharmaceuticals is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Catalyst Stock. However, Catalyst Pharmaceuticals' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 21.15 | Real 21.4 | Hype 21.15 | Naive 19.67 |
The intrinsic value of Catalyst Pharmaceuticals' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Catalyst Pharmaceuticals' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Catalyst Pharmaceuticals helps investors to forecast how Catalyst stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Catalyst Pharmaceuticals more accurately as focusing exclusively on Catalyst Pharmaceuticals' fundamentals will not take into account other important factors: Catalyst Pharmaceuticals Total Value Analysis
Catalyst Pharmaceuticals is currently projected to have valuation of 2.08 B with market capitalization of 2.52 B, debt of 3.56 M, and cash on hands of 220.79 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Catalyst Pharmaceuticals fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
2.08 B | 2.52 B | 3.56 M | 220.79 M |
Catalyst Pharmaceuticals Investor Information
About 82.0% of the company shares are held by institutions such as insurance companies. The book value of Catalyst Pharmaceuticals was currently reported as 5.54. The company had not issued any dividends in recent years. Based on the key indicators related to Catalyst Pharmaceuticals' liquidity, profitability, solvency, and operating efficiency, Catalyst Pharmaceuticals is not in a good financial situation at this time. It has a very high probability of going through financial hardship in December.Catalyst Pharmaceuticals Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Catalyst Pharmaceuticals has an asset utilization ratio of 84.7 percent. This suggests that the Company is making $0.85 for each dollar of assets. An increasing asset utilization means that Catalyst Pharmaceuticals is more efficient with each dollar of assets it utilizes for everyday operations.Catalyst Pharmaceuticals Ownership Allocation
Catalyst Pharmaceuticals holds a total of 119.27 Million outstanding shares. The majority of Catalyst Pharmaceuticals outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Catalyst Pharmaceuticals to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Catalyst Pharmaceuticals. Please pay attention to any change in the institutional holdings of Catalyst Pharmaceuticals as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.Catalyst Pharmaceuticals Profitability Analysis
The company reported the previous year's revenue of 398.2 M. Net Income was 71.41 M with profit before overhead, payroll, taxes, and interest of 160.02 M.About Catalyst Pharmaceuticals Valuation
Our relative valuation model uses a comparative analysis of Catalyst Pharmaceuticals. We calculate exposure to Catalyst Pharmaceuticals's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Catalyst Pharmaceuticals's related companies.Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida. Catalyst Pharm operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 76 people.
Catalyst Pharmaceuticals Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 113.8 M | |
| Forward Price Earnings | 10.627 |
Additional Tools for Catalyst Stock Analysis
When running Catalyst Pharmaceuticals' price analysis, check to measure Catalyst Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Catalyst Pharmaceuticals is operating at the current time. Most of Catalyst Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Catalyst Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Catalyst Pharmaceuticals' price. Additionally, you may evaluate how the addition of Catalyst Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.